Sony Corp. is planning to launch human genome analysis operations by creating a joint venture with U.S. genome sequencing equipment maker Illumina Inc., sources said Wednesday.
The joint venture will conduct genome information analysis and sell information compiled in databases to drugmakers in Japan, the sources said. Sony has targeted the medical field as a core segment.
The joint venture will be set up by Sony, subsidiary M3 Inc., which operates a medical information website, and Illumina.
The new company plans to conduct genome analysis for drugmakers and research institutions by using Illumina’s equipment.
The utilization of genome information is believed to allow estimation of susceptibility to some diseases and appropriate treatment. Sony established a medical equipment company in April with optical equipment maker Olympus Corp.